In July 2025 , letters were sent to 17 pharmaceutical companies, including Novo Nordisk, requesting commitments to lower prices by September 29
Don't wait to reveal your skin's true potential - visit us today and take the first step towards a more confident, glowing you.
In addition, in a cardiovascular outcome study involving patients with type 2 diabetes, of whom more than 80% had a history of cardiovascular disease, semaglutide treatment lowered the rates of 3-point MACE (myocardial infarction, stroke and cardiovascular death) [31]
Sayed, N
Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge, a short-term program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay per month